Abstract
Background
The prognosis of gastric cancer patients with peritoneal dissemination is poor. Recently, chemotherapy with S-1 plus cisplatin has been shown to be highly effective for advanced gastric cancer.
Methods
In 41 patients diagnosed with either macro- or microscopic peritoneal dissemination by staging laparoscopy, and receiving induction chemotherapy with S-1 plus cisplatin between August 2002 and February 2008, response of peritoneal lesions to the induction chemotherapy and the outcome of the following surgery were retrospectively evaluated.
Results
Of 41 patients identified, 38 patients (93%) completed two cycles. Among grade 3 or 4 adverse effects, neutropenia was most frequently observed (9 patients; 22%). After chemotherapy, 32 patients (78%) underwent surgery and R0 resection was accomplished in 22 patients. Although objective response by Response Evaluation Criteria in Solid Tumors (RECIST) was recorded in only four patients (10%), peritoneal dissemination disappeared in 19 patients (46%). Patients with limited peritoneal metastasis, negative peritoneal cytology, or response of the primary lesion were more likely to exhibit disappearance of the peritoneal dissemination. Median survival time of all patients was 20.4 months. Patients with R0 resection had median survival time of 43.2 months, which was significantly longer than for those with noncurative resection (12.6 months) or without surgery (10.3 months).
Conclusions
Limited peritoneal dissemination of gastric origin is highly sensitive to induction chemotherapy with S-1 plus cisplatin. Resection after disappearance of peritoneal metastasis could cure some patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Glehen O, Kwiatkowski F, Sugarbaker P, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92.
Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 2005;92(3):370–5.
Van Cutsem E, Moiseyenko V, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7.
Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996–2004.
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21.
Cunningham D, Allum W, Stenning S, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouche O. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol. 2007;25:4510.
Satoh S, Hasegawa S, Ozaki N, et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer. 2006;9(2):129–35.
Fujitani K, Sasako M, Iwasaki Y, et al. A phase II study of preoperative chemotherapy (CX) with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancer: JCOG 0210. J Clin Oncol. 2007;25:4609.
Oshima T, Yamada R, Hatori S, Kunisaki C, Imada T. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer. Oncol Rep. 2006;16(2):361–6.
Ishizone S, Maruta F, Saito H, et al. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy. 2006;52(6):301–7.
Akatsu Y, Saikawa Y, Kubota T, et al. Clinical and pathological disappearance of peritoneal dissemination in a patient with advanced gastric cancer receiving chemotherapy with S-1 and low-dose cisplatin. Gastric Cancer. 2004;7(2):128–33.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English ed. Gastric Cancer. 1998;1(1):10–24.
Cancer JRSfG. The general rules for gastric cancer study, 1st English ed. Tokyo: Kanehira Shuppan; 1995.
Gilly F, Carry P, Sayag A, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41(2):124–9.
Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.
Wittekind C, Compton C, Greene F, Sobin L. TNM residual tumor classification revisited. Cancer. 2002;94(9):2511–6.
Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139(1):20–6.
Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32(6):661–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Okabe, H., Ueda, S., Obama, K. et al. Induction Chemotherapy with S-1 Plus Cisplatin Followed by Surgery for Treatment of Gastric Cancer with Peritoneal Dissemination. Ann Surg Oncol 16, 3227–3236 (2009). https://doi.org/10.1245/s10434-009-0706-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-009-0706-z